Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union
Journal of Cystic Fibrosis · 2025-01 · 24 (1) · 125-132
DOI: 10.1016/j.jcf.2024.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-01. Verfasst von Enrico Costa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Utrecht World Health Organization Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharma…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Drug Approval, Cystic Fibrosis Transmembrane Conductance Regulator, Chloride Channel Agonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: The objective of this study was to assess the differential times of submission and approval of CFTR modulators in the United States (US) and the European Union (EU). METHODS: By collecting publicly available data from the websites of the Food and Drug Administration and the European Medicines Agency, we quantified differential times in submission, review duration, and approvals of initial marketing authorization and variation of indications of CFTR modulators in the US and the EU by December 31, 2023. RESULTS: Applications regarding marketing of 4 CFTR modulators were submitted 103 (SD ±143) days later in the EU than in the US: 31 (SD ±39) days later for initial approval, and 124 (SD ±155) days for supplemental indications. The regulatory review process was completed in 181 days [IQR, 179 - 182] in the US and 325 days [IQR, 276 - 382] in the EU: 167 days [IQR, 102 - 232] in the US and 346 days [IQR, 302 - 400] in the EU for first approvals, 181 days [IQR, 181 - 182] in the US and 324 days [IQR, 264 - 382] in the EU for supplemental indication approvals. CFTR modulators were approved 267 (SD 143) days later in the EU than in the US: 220 (SD ±76) days for initial approval and 280 (SD ±157) days for supplemental indications. CONCLUSION: We found significant differences in times of submission and for approval of CFTR modulators between the US and EU, whereby initial approvals and subsequent indication approvals were always first granted in the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Utrecht World Health Organization Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands. Electronic addre…
- Section of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
- Inserm, Bordeaux Population Health Research Center, University Bordeaux, Bordeaux, France.
- Cystic Fibrosis Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
- Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO, USA.
Zitieren
APA
Costa, E., Girotti, S., Mathieu, C., Castellani, C., Ross, J. S., Taylor-Cousar, J. L., & Leufkens, H. G. M. (2025). Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. Journal of Cystic Fibrosis, 24(1), 125-132. https://doi.org/10.1016/j.jcf.2024.08.002
Vancouver
Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, et al. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. Journal of Cystic Fibrosis. 2025;24(1):125-132. doi:10.1016/j.jcf.2024.08.002
BibTeX
@article{Costa2025,
author = {Costa, Enrico and Girotti, Silvia and Mathieu, Clément and Castellani, Carlo and Ross, Joseph S and Taylor-Cousar, Jennifer L and Leufkens, Hubert G M},
title = {Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {1},
pages = {125--132},
doi = {10.1016/j.jcf.2024.08.002}
}
EUVIMED